Toll Free: 1-888-928-9744

Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 33 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Review, H1 2016', provides in depth analysis on Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2)
- The report reviews Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) Overview 6 Therapeutics Development 7 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Stage of Development 7 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Therapy Area 8 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Indication 9 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Products under Development by Companies 12 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Companies Involved in Therapeutics Development 20 A. Menarini Industrie Farmaceutiche Riunite Srl 20 AlbireoPharma 21 Takeda Pharmaceutical Company Limited 22 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Drug Profiles 23 A-3914 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 A-5425 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 DTI-100 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ibodutant - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 nepadutant - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Antagonize NK 1 and NK 2 Receptors for Pain - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 TAK-480 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Dormant Projects 30 Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Discontinued Products 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 20 Pipeline by AlbireoPharma, H1 2016 21 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 22 Dormant Projects, H1 2016 30 Discontinued Products, H1 2016 31


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Mechanism of Actions, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify